Evidence map›Paper›PMID 41661673›Full record

ArticleCancer research2026

Subcellular Redistribution of Endomembrane GPR15 Promotes NAD+-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer.

Zhiying Yue, Wentao Dai, Zhuoran Cao, Bin Hu, Ziyuan Wang, Xinrun Ma, Da Qin, Taiyu Zhang, Qingqing Sang, Jing Mei and 9 more

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The role of NADFrontiers in oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zhiying Yue *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-5625-2392
Wentao Dai *Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Laboratory of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Fudan University, Shanghai, China.ORCID 0000-0002-0762-919X
Zhuoran Cao *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0003-5334-8043
Bin Hu *Department of Gastroenterology, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-6441-8487
Ziyuan WangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0003-1559-8271
Xinrun MaPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-8749-4474
Da QinPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-0096-1130
Taiyu ZhangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0003-3832-7308
Qingqing SangDepartment of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0008-6501-1911
Jing MeiPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0003-7642-0183
Tianci YuPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-5847-6536
Yong ZhouPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0007-7538-1548
Zai LuoDepartment of Gastrointestinal Surgery, General Surgery Clinical Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0006-7727-3703
Junming XuDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-9687-5551
Zengjin YuanShanghai Novopathway Biotechnology Co. Ltd, Shanghai, China.ORCID 0009-0009-2589-012X
Yuan-Yuan LiShanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Laboratory of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Fudan University, Shanghai, China.ORCID 0000-0001-8755-4695
Jinyan ZhangDepartment of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0009-0003-5168-8327
Chen HuangDepartment of Gastrointestinal Surgery, General Surgery Clinical Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-1840-5765
Zhengfeng YangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0003-2011-9466

Funding

Innovation Promotion Program of NHC and Shanghai Key Labs SIBPT RC2023-01National Key Research and Development Program of China Stem Cell and Translational Research (Stem Cell and Translational Research) 2020YFA0112900National Natural Science Foundation of China (NSFC) 32000472National Natural Science Foundation of China (NSFC) 81971555National Natural Science Foundation of China (NSFC) 82272645National Natural Science Foundation of China (NSFC) 82303378National Natural Science Foundation of China (NSFC) 82372987Natural Science Foundation of Shanghai Municipality () 23ZR1451800Science and Technology Innovation Plan Of Shanghai Science and Technology Commission () 23JC1401306Shanghai Academy of Science & Technology SKY2022003Shanghai Municipal Health Commission () 2022YQ065Shanghai Pujiang Program 19PJ1408700Shanghai Rising-Star Program 23QA1408100
6 · The paper itself

Abstract

G protein-coupled receptors (GPCR) are increasingly recognized for their organelle-specific functions in cancer. A better understanding of the mechanisms governing their dynamic subcellular distribution and functional coordination is essential for developing spatially targeted therapies that exploit the subcellular signaling networks of GPCRs. In this study, we found that Golgi-localized GPR15 underwent spatiotemporal trafficking to enhance 5-fluorouracil (5-FU) chemosensitivity in colorectal cancer. Dependent on Gαq, GPR15 associated with and restrained PARP4 enzymatic activity in the Golgi apparatus to drive cytosolic NAD+ accumulation. MGST1 interacted with and navigated GPR15 redistribution to mitochondria to increase mitochondrial NAD+ abundance, which fueled central carbon metabolism and activated downstream metabolic networks to prime tumors for 5-FU cytotoxicity. Treatment with the PARP inhibitor rucaparib showed potent synergy with 5-FU and demonstrated robust tumor suppression in patient-derived organoids and xenograft models through NAD+-mediated metabolic perturbation. This work establishes spatially encoded GPCR signaling as a druggable axis to potentiate chemotherapy efficacy, redefining intracellular receptor trafficking as an important regulator of metabolic plasticity in cancer therapy. SIGNIFICANCE: GPCR redistribution spatially regulates NAD+ metabolism and can be harnessed with clinically available PARP inhibitors to enhance chemosensitivity, offering a strategy to target nongenetic adaptive mechanisms for treating colorectal cancer.

Indexed as

Colorectal NeoplasmsFluorouracilNADReceptors, G-Protein-CoupledAnimalsCell Line, TumorGolgi ApparatusHumansMetabolic ReprogrammingMiceMitochondriaSignal TransductionXenograft Model Antitumor AssaysFluorouracilNADReceptors, G-Protein-Coupled

Identifiers

PMID41661673
PMCPMC13136880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.